QUAIL-100 for Children With Blood Cancers After Stem Cell Transplant
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a new experimental treatment called QUAIL-100 in children and young adults who have had a stem cell transplant for a serious blood cancer. The treatment is designed to help the immune system fight remaining cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You weigh at least 10 kg (about 22 pounds)
- You have received a stem cell transplant for a high-risk blood cancer and your blood cells have started growing back
- You are healthy enough for treatment (your doctor rates your overall health/ability to do daily activities as fair or better)
- If you could become pregnant, you agree to use birth control during the study
- You do not have moderate-to-severe graft-versus-host disease (a condition where transplanted cells attack your body)
- You have not received any cancer-fighting treatment in the past 3 weeks and will not receive any in the next 3 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of four medicines (cyclophosphamide, abatacept, vedolizumab, and ruxolitinib) to prevent graft-versus-host disease (GVHD) after a stem cell transplant for children and young adults with certain blood cancers. The goal is to see if this approach reduces the risk of GVHD, a serious complication where donor cells attack the body.
This trial tests a new drug called QLS2309 for people with certain blood cancers that have come back or not responded to other treatments. The drug targets a protein called CD70 on the cancer cells, and this study aims to find the safest dose.
This trial tests a new drug (QLC2519) given alongside a standard chemotherapy regimen called VDC/IE for children and teens with sarcoma. The goal is to see if it can help treat their cancer more effectively.
This trial tests an investigational drug (QLS2313) for people with certain blood cancers that have returned or stopped responding to treatment. The drug is given as an injection and may help shrink or control the cancer. This is a phase 1 trial, so the main goal is to find the best dose and see how safe it is.
This trial tests a new drug called QL0911 to help raise platelet counts in people with cancer whose chemo has caused low platelets. The goal is to see if it can prevent delays in treatment.
This trial tests a new medicine for children with a condition called immune thrombocytopenia (ITP), which causes low blood platelets and easy bruising or bleeding. It may help increase platelet counts when standard treatments haven't worked.
Hear when a new Acute Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.